



TO: Pharmacy and Durable Medical Equipment, Devices and Supplies (MEDS) Providers
RE: Upcoming Changes to Pharmacy Claims for Omnipod and VGO Insulin Delivery Products

The purpose of this bulletin is to notify providers of upcoming changes to coverage of Omnipod (Pods) and VGO (wearable “patch-like”) insulin delivery devices for HUSKY A, HUSKY B, HUSKY C, and HUSKY D clients.

Currently, the Department of Social Services (DSS) pays for insulin pumps via the Durable Medical Equipment (DME) benefit. Beginning **February 2, 2022**, Omnipod Pods and VGO devices will also be payable through pharmacy Point of Sale (POS) with an approved Prior Authorization meeting medical necessity regardless of preferred status. A new Prior Authorization form will be available via www.ctdssmap.com under the Pharmacy section.

These insulin delivery products, when processed as a pharmacy POS claim, will be subject to the Diabetic Preferred Product List. Preferred insulin delivery products are recommended and should be prescribed unless the prescribing provider’s clinical judgement is in opposition. The full list of preferred products is published on the Connecticut Medical Assistance Program (CMAP) Web site www.ctdssmap.com under the Pharmacy section. From the Home page, go to Pharmacy Information → Preferred Drug List Information → Diabetic Supplies Preferred Product List. The Diabetic Supplies Preferred Product List will be updated prior to **February 2, 2022** and will list the preferred insulin delivery product(s).

Please note that the Omnipod Personal Diabetes Manager (PDM) will be provided at no additional charge to patients from the manufacturer (Insulet) and Pharmacies

should not submit pharmacy claims for the PDM to the CMAP.

Please note that insulin pumps, including Omnipod (Pods only) and VGO, will continue to be a covered service under the DME benefit.

Pharmacy providers submitting claims for dual eligible beneficiaries for Medicare Part B covered supplies will continue to follow the billing guidelines published in Provider Bulletin [PB 2020-01](#).

Effective February 2, 2022, the CMAP will accept claims submitted to Medicare and Third Party Liability (TPL) as well as pharmacy claims billed directly to CMAP for VGO insulin delivery products via the pharmacy POS.